Triplet therapy for advanced renal cell carcinoma may soon be an option, after results show that adding cabozantinib to dual immune checkpoint inhibition improved progression-free survival.
Medscape Medical News
Triplet therapy for advanced renal cell carcinoma may soon be an option, after results show that adding cabozantinib to dual immune checkpoint inhibition improved progression-free survival.
Medscape Medical News
